Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating income | -$25.5M | -$28.7M |
| Net income | -$22.8M | -$28.8M |
| EPS (diluted) | -$0.30 | -$0.30 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$19.9M | -$20.1M |
| Capital expenditures | $174K | $6.00K |
| Free cash flow | -$20.1M | -$20.1M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $11.1M | $5.20M |
| Total assets | $13.4M | $7.58M |
| Total liabilities | $10.1M | $11.4M |
| Shareholders' equity | $3.30M | -$3.80M |
| Retained earnings | -$401M | -$429M |
| Shares (wtd avg diluted) | 76.5M | 95.9M |
Every figure is extracted from ONCOLYTICS BIOTECH INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.